Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where M. Takusagawa is active.

Publication


Featured researches published by M. Takusagawa.


American Journal of Hypertension | 1998

QT Dispersion in Dipper- and Nondipper-Type Hypertension

Isao Kohno; M. Takusagawa; D.F. Yin; Mitsuaki Okutani; Yasuaki Mochizuki; Soichi Sano; Tsukasa Ishihara; Hiroyuki Ishii; Hiroshi Ijiri; Sadayoshi Komori; Kohji Tamura

The aim of this study was to identify the relationship of QT dispersion on 12-lead electrocardiograms and left ventricular mass index on echocardiograms associated with the circadian rhythm of blood pressure (BP). Heart rate and BP were monitored every 30 min for 48 h in 62 patients with essential hypertension using an ambulatory BP monitoring device. The patients were divided into four groups according to gender and circadian BP pattern (nocturnal BP dipper or nondipper). The patients were classified as dippers if their daytime BP decreased by at least 10% during the night and all the other subjects were classified as nondippers. Age, body mass index, and 48-h mean BP were similar among the four groups. During the night-rest period, the systolic and diastolic BP were significantly decreased in dipper-type hypertensives. The maximum QTc interval and QTc dispersion were longer in nondippers than in dippers. Left ventricular mass index (LVMI) had a tendency to increase in nondippers. The nocturnal reduction of BP significantly correlated with QTc dispersion and LVMI. The QTc dispersion significantly correlated with LVMI and interventricular septum thickness.


Chronobiology International | 2000

Effect of imidapril in dipper and nondipper hypertensive patients: comparison between morning and evening administration.

Isao Kohno; Hiroshi Ijiri; M. Takusagawa; D.F. Yin; Souichi Sano; Tsukasa Ishihara; Takao Sawanobori; Sadayoshi Komori; Kohji Tamura

The purpose of the study was to identify differences in the patterns of efficacy and duration of effects of imidapril administered at different times of the day (morning versus evening) in dipper and nondipper hypertensive patients. Twenty patients with untreated hypertension were classified into two groups: dippers (n = 9) and nondippers (n = 11). Imidapril (10 mg) was given at 07:00 or 18:00 for 4 weeks in a crossover fashion. Blood pressure (BP) and heart rate (HR) were monitored before and after morning and evening treatment every 30 min for 48h by ambulatory BP monitoring (ABPM). In dipper hypertension, the mean 48h BP was reduced with both doses. The decrease in the diurnal BP was stronger when the drug was administered in the evening than morning, but without significant difference. In nondipper hypertension, the systolic BP decreased at night with both doses, but the extent of the nocturnal reduction in systolic BP was greater after morning therapy. There were no significant differences in the decrease in BP during the day or night between the morning and evening administrations. When imidapril was administered in the morning, its serum concentration reached a maximum at 16:00, and when the drug was administered in the evening, it reached a maximum at 6:00. In dipper hypertension, the time taken for the blood concentration of imidapril to reach a maximum changed depending on its time of administration, and the time when the maximum antihypertensive effect of the drug appeared was different. In nondipper hypertension, decreases in the BP were confirmed at night regardless of the time of administration; this might be caused by angiotensin converting enzyme (ACE) inhibitors effectively blocking the BP from increasing by activating the parasympathetic nervous system. Therefore, when assessing the effectiveness of antihypertensive agents, factors such as the various patterns of BP before therapy and administration time must be considered. (Chronobiology International, 17(2), 209–219, 2000)


Journal of Cardiovascular Pharmacology and Therapeutics | 2000

The Inhibitory Effects of Carvedilol Against Arrhythmias Induced by Coronary Reperfusion in Anesthetized Rats

M. Takusagawa; Sadayoshi Komori; Kuniyoshi Matsumura; Mitsuru Osada; Isao Kohno; Ken Umetani; Tsukasa Ishihara; Takao Sawanobori; Hiroshi Ijiri; Kohji Tamura

Background: Previous study has shown the antiarrhythmic effects of carvedilol on isolated rat hearts, but little is known about the mechanism of this protective action. This article examines the inhibitory effect of carvedilol against arrhythmias induced by reperfusion in anesthetized rats. In addition, the results are compared with those with propranolol, super oxide dismutase (SOD) plus catalase, and a combination of both in order to elucidate the mechanism of the protective actions. Methods and Materials: Ninety percent of the rats in the control group showed lethal ventricular fibrillation (VF). Carvedilol at the doses of 0.03, 0.1, and 0.3 mg/kg significantly reduced the incidence of lethal VF to 0%, 0%, and 10%, respectively ( P < .05). In contrast, propranolol at the doses of 0.3, 1.0, and 3.0 mg/kg and SOD (35,000 units/kg) plus catalase (400,000 units/kg) did not reduce the incidence of lethal VF (80%, 60%, 70%, and 70%, respectively). However, administration of a combination of propranolol (1.0 mg/kg) and SOD plus catalase completely inhibited the occurrence of lethal VF to 0% ( P < .05). Conclusion: These results indicate that carvedilol has the inhibitory effect against reperfusion arrhythmias in rats and suggest that the mechanism of action of this compound is related to the combined effects of beta-blocking and antioxidant.


Molecular and Cellular Biochemistry | 2000

Protein kinase C is involved in cardioprotective effects of ischemic preconditioning on infarct size and ventricular arrhythmia in rats in vivo

Kuniyoshi Matsumura; Sadayoshi Komori; M. Takusagawa; Mitsuru Osada; Fuminori Tanabe; Masahiko Ito; Kohji Tamura

Protein kinase C (PKC) has been known to play an important role in ischemic preconditioning (IP). This study was designed to examine whether the translocation of PKC is associated with the cardioprotective effects of IP in vivo on infarct size and ventricular arrhythmias in a rat model.Using anesthetized rats, heart rate, systolic blood pressure, infarct size and ventricular arrhythmias during 45 min of coronary occlusion were measured. PKC activity was assayed in both the cytosolic and cell membrane fraction . Brief 3-min periods of ischemia followed by 10 min of reperfusion were used to precondition the myocardium. Calphostin C was used to inhibit PKC.Infarct size was significantly reduced by IP (68.1 (2.5)%, mean (S.E.) vs. 45.2 (3.4)%, p < 0.01). The reduction in infarct size by IP was abolished by pretreatment with calphostin C. The total number of ventricular premature complex (VPC) during 45 min of coronary occlusion was reduced by IP (1474 (169) beats/45 min vs. 256 (82) beats/45 min, p < 0.05). The reduction the total number of VPC induced by IP was abolished by the administration of calphostin C before the episode of brief ischemia. The same tendency was observed in the duration of ventricular tachycardia and the incidence of ventricular fibrillation. PKC activity in the cell membrane fraction transiently increased immediately after IP (100 vs. 142%, p < 0.01) and returned to baseline 15 min after IP. Pretreatment with calphostin C prevented the translocation of PKC.The translocation of PKC plays an important role in the cardioprotective effect of IP on infarct size and ventricular arrhythmias in anesthetized rats.


Pacing and Clinical Electrophysiology | 2000

Improvement of exercise tolerance by single lead VDD pacemaker: evaluation using cardiopulmonary exercise test.

Hiroshi Ijiri; Sadayoshi Komori; Isao Kohno; Soichi Sano; D.F. Yin; M. Takusagawa; Takashi Iida; Kimio Yamamoto; Mitsuru Osada; Takao Sawanobori; Tsukasa Ishihara; Ken Umetani; Kohji Tamura

We used a Cardiopulmonary test to assess the physiological benefit of single lead VDD pacing in ten patients (six men, four women; aged 32–84 years, mean 69 years) with atrioventricular block. Maximal symptom‐limited treadmill exercise test using a ramp protocol was performed under VDD and VVIR or VVI pacing (VVI) in random sequence. The pacemaker was then programmed to the VDD mode, and Holter ECG was recorded in nine patients. Compared with findings during the VVI, the VDD mode had a greater chronotropic response (mean maximal heart rate, VDD 106 ± 17 beats/mm vs VVI 79 ± 19 beats/min, P = 0.03), and was associated with prolongation of exercise duration (VDD 11.2 ± 2.9 minute vs VVI 10.5 ± 3.1 minute; P = 0.01), and the onset of anaerobic threshold at a higher oxygen uptake (VDD 12.4 ± 3.4 mL/min per kilogram vs WI 10.0 ± 2.1 mL/min per kilogram; P < 0.01). Atriai sensing was recognized in almost all normal sinus P waves for all cases examined using Holter ECG. Thus, chronotropic response during exercise by VDD pacemaker improved exercise tolerance, indicating that a VDD pacemaker might be useful for patients requiring physical activity.


Molecular and Cellular Biochemistry | 1999

Antiarrhythmic effect of magnesium sulfate against occlusion-induced arrhythmias

Sadayoshi Komori; Binghong Li; Kuniyoshi Matsumura; M. Takusagawa; Soichi Sano; Isao Kohno; Mitsuru Osada; Takao Sawanobori; Tsukasa Ishihara; Ken Umetani; Hiroshi Ijiri; Kohji Tamura

The antiarrhythmic effect of magnesium sulfate (Mg) as well as the hemodynamics were studied using the coronary ligation and reperfusion models in rats.In the study on coronary ligation arrhythmia, i.v. administration of Mg (0.6, 2, 6, 20 and 60 \sgmaelig;mol) was conducted at 5 min after coronary ligation. Mg had an action to decrease the total number of premature ventricular contraction (PVC), the duration of ventricular tachycardia (VT), the frequency of VT and ventricular fibrillation (Vf) and the mortality ratio for 30 min after coronary ligation. In the 6-60 \sgmaelig;mol groups, significant antiarrhythmic action (p < 0.01 vs. control) was attained.In the study on reperfusion arrhythmia, i.v. administration of Mg (20, 60 and 200 \sgmaelig;mol) was conducted at 4 min after coronary ligation, and at 1 min after ligation, the coronary artery was reperfused. Mg had an action to decrease the frequency of Vf, the mortality ratio and the duration of VT and Vf and to extend the interval between the initiation of reperfusion and the occurrence of VT and Vf for 10 min after reperfusion. In the 200 \sgmaelig;mol group, significant antiarrhythmic action (p < 0.05 vs. control) was attained. Administration of Mg decreased the heart rate and blood pressure.We concluded that Mg can control myocardial ischemia-induced and reperfusion-induced arrhythmia and that sudden cardiac death which occurs as a result of arrhythmia can be prevented.


American Journal of Hypertension | 1998

Limited Reproducibility of Circadian Variation in Blood Pressure Dippers and Nondippers

Yasuaki Mochizuki; Mitsuaki Okutani; Ying Donfeng; Hiroshi Iwasaki; M. Takusagawa; Isao Kohno; Sunao Mochizuki; Ken Umetani; Hiroyuki Ishii; Hiroshi Ijiri; Sadayoshi Komori; Kohji Tamura


Japanese Circulation Journal-english Edition | 2000

Cardiac arrhythmias and left ventricular hypertrophy in dipper and nondipper patients with essential hypertension

Hiroshi Ijiri; Isao Kohno; D.F. Yin; Hiroshi Iwasaki; M. Takusagawa; Takashi Iida; Mitsuru Osada; Ken Umetani; Tsukasa Ishihara; Takao Sawanobori; Hiroyuki Ishii; Sadayoshi Komori; Kohji Tamura


Japanese journal of geriatrics | 1997

Circadian variation of blood pressure and heart rate in normotensive pre- and postmenopausal women

Li B; Hiroshi Ijiri; D.F. Yin; M. Takusagawa; Hiroshi Iwasaki; Yasuaki Mochizuki; Mitsuaki Okutani; Isao Kohno; Mochizuki S; Sadayoshi Komori; Kohji Tamura


American Journal of Hypertension | 1999

Chronotherapy of dipper and non-dipper type hypertension with bunazisin-retard : morning versus evening administration.

Isao Kohno; Hiroshi Ijiri; M. Takusagawa; D.F. Yin; Hiroshi Iwasaki; Takao Sawanobori; Ken Umetani; Tsukasa Ishihara; Sadayoshi Komori; Kohji Tamura

Collaboration


Dive into the M. Takusagawa's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Isao Kohno

University of Yamanashi

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Ken Umetani

University of Yamanashi

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Takashi Iida

University of Yamanashi

View shared research outputs
Top Co-Authors

Avatar

Ken Umetani

University of Yamanashi

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge